Home | Welcome to Contract Pharma   
Last Updated Tuesday, March 3 2015

Print

Search Results for 'Financial Report: Merck'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published February 4, 2015
Patent expiries and divestitures impact results Read More »
Published October 28, 2014
Merck 3Q Revenues: $10.6 billion  (-4%) 3Q Earnings: $842 million (-27%) YTD Revenues: $31.8 billion (-3%) YTD Earnings: $4.6 billion (+24%) Comments: Pharmaceutical sales were $9.1 billion in the quarter, down 4%. JANUVIA/JANUMET sales wer… Read More »
Published July 30, 2014
Second quarter profits more than doubled, while sales decreased by 1% Read More »
Published October 26, 2012
Key products help offset August Singulair patent expiry Read More »
Published July 27, 2012
Pharma sales up 2%, hurt by Remicade settlement Read More »
Published October 31, 2011
Revenues up 8% Read More »
Published July 30, 2010
Singulair sales in the quarter were flat at $1.3 billion. Remicade sales were $669 million (+18%). Read More »
Published April 21, 2009
Worldwide sales of Singulair were $1.1 billion (-4%). Combined global sales of Zetia and Vytorin, as reported by the Merck/Schering-Plough partnership, were $945 million (-23%). Read More »
Published October 22, 2008
Merck 3Q Revenues: $5.9 billion (-2%) 3Q Earnings: $1.1 billion (-28%) YTD Revenues: $17.8 billion (-1%) YTD Earnings: $6.2 billion (+26%) Comments: Januvia sales were $379 million in the quarter (+105%). Sales of Isentress were $107 m… Read More »
Published January 30, 2007
Merck 4Q Revenues: $6 billion (+5%) 4Q Earnings: $473.9 million* (earnings were $1.1 billion 4Q2005) FY Revenues: $22.6 billion (+3%) FY Earnings: $4.4 billion (-4%) Comments: Singulair sales were $960 million for the quarter, up… Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On